BACKGROUND: It is well known that obesity is a risk factor for severe cardiovascular complications, such as coronary heart disease, heart failure, stroke, venous thromboembolic disease, and atrial fibrillation. Left ventricle (LV) and left atrium (LA) enlargement is a characteristic feature of these patients with the consequent cardiovascular risk. Factors other than hemodynamic may influence LA remodeling. The aim of the study is to evaluate the relationship between adiponectin and LA size in uncomplicated obese patients. METHODS: Seventy-four asymptomatic obese patients and an age- and sex-matched control group (N = 70) were recruited. A detailed clinical, echocardiographic, and analytical study was performed. Insulin resistance was assessed using the homeostasis model assessment for insulin resistance (HOMA-IR) method. Insulin sensitivity was assessed measuring serum total adiponectin concentrations. RESULTS: Adiponectin levels were lower in the obese group (P < 0.001) and particularly so in those obese participants with enlarged LA (32%; P < 0.0005). LA sizes were higher in the obese group (P < 0.0005). Adiponectin displayed significant correlations with body mass index, glucose, insulin, high-density lipoprotein cholesterol, and triglyceride concentrations as well as HOMA-IR (P < 0.001 for all). Adiponectin displayed significant correlations with LV mass and LA size, diastolic and systolic cardiac volumes and diameters, and cardiac output (P < 0.001 for all). Adiponectin correlations with LA size (r = -0.429; P < 0.001) persisted after adjustment for HOMA-IR, age, sex, and LV mass. CONCLUSIONS: A novel inverse relationship between adiponectin and LA size independent of age, sex, insulin resistance, and LV mass appears in our series. Adiponectin could be a link between adipose tissue and the heart, having an influence on cardiac remodeling.
BACKGROUND: It is well known that obesity is a risk factor for severe cardiovascular complications, such as coronary heart disease, heart failure, stroke, venous thromboembolic disease, and atrial fibrillation. Left ventricle (LV) and left atrium (LA) enlargement is a characteristic feature of these patients with the consequent cardiovascular risk. Factors other than hemodynamic may influence LA remodeling. The aim of the study is to evaluate the relationship between adiponectin and LA size in uncomplicated obesepatients. METHODS: Seventy-four asymptomatic obesepatients and an age- and sex-matched control group (N = 70) were recruited. A detailed clinical, echocardiographic, and analytical study was performed. Insulin resistance was assessed using the homeostasis model assessment for insulin resistance (HOMA-IR) method. Insulin sensitivity was assessed measuring serum total adiponectin concentrations. RESULTS:Adiponectin levels were lower in the obese group (P < 0.001) and particularly so in those obeseparticipants with enlarged LA (32%; P < 0.0005). LA sizes were higher in the obese group (P < 0.0005). Adiponectin displayed significant correlations with body mass index, glucose, insulin, high-density lipoprotein cholesterol, and triglyceride concentrations as well as HOMA-IR (P < 0.001 for all). Adiponectin displayed significant correlations with LV mass and LA size, diastolic and systolic cardiac volumes and diameters, and cardiac output (P < 0.001 for all). Adiponectin correlations with LA size (r = -0.429; P < 0.001) persisted after adjustment for HOMA-IR, age, sex, and LV mass. CONCLUSIONS: A novel inverse relationship between adiponectin and LA size independent of age, sex, insulin resistance, and LV mass appears in our series. Adiponectin could be a link between adipose tissue and the heart, having an influence on cardiac remodeling.
Authors: Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa Journal: Biochem Biophys Res Commun Date: 1999-04-02 Impact factor: 3.575
Authors: Vitantonio Di Bello; Ferruccio Santini; Andrea Di Cori; Andrea Pucci; Caterina Palagi; Maria Grazia Delle Donne; Paola Fierabracci; Alessandro Marsili; Enrica Talini; Monica Giannetti; Ombretta Biadi; Alberto Balbarini; Mario Mariani; Aldo Pinchera Journal: J Am Soc Echocardiogr Date: 2006-08 Impact factor: 5.251
Authors: Josef V Silha; Michal Krsek; Jan V Skrha; Petr Sucharda; B L G Nyomba; Liam J Murphy Journal: Eur J Endocrinol Date: 2003-10 Impact factor: 6.664
Authors: Juan Ybarra; Jose M Pou; Francesc Planas; Carlos Ballesta-López; Fernando Echevarne; June H Romeo; Francisco Navarro-López Journal: Endocr Pract Date: 2007-10 Impact factor: 3.443
Authors: Teresa S M Tsang; Marion E Barnes; Yoko Miyasaka; Stephen S Cha; Kent R Bailey; Grace C Verzosa; James B Seward; Bernard J Gersh Journal: Eur Heart J Date: 2008-07-08 Impact factor: 29.983
Authors: Ignacio Garcia-Marirrodriga; Cesar Amaya-Romero; Gabriel Patiño Ruiz-Diaz; Sandra Férnandez; Carlos Ballesta-López; Jose M Pou; June H Romeo; Gemma Vilahur; Gemma Vilhur; Lina Badimon; Juan Ybarra Journal: Obes Surg Date: 2012-04 Impact factor: 4.129
Authors: Kevin P Cohoon; Matylda Mazur; Robert D McBane; Siva Ketha; Naser Ammash; Waldemar E Wysokinski Journal: Int J Cardiol Date: 2014-12-03 Impact factor: 4.164
Authors: Aurelian Bidulescu; Jiankang Liu; Solomon K Musani; Ervin R Fox; Tandaw E Samdarshi; Daniel F Sarpong; Viola Vaccarino; Peter W Wilson; Donna K Arnett; Rebecca Din-Dzietham; Herman A Taylor; Gary H Gibbons Journal: Circ Heart Fail Date: 2011-08-12 Impact factor: 8.790
Authors: Jared W Magnani; Faye L Lopez; Elsayed Z Soliman; Richard F Maclehose; Richard S Crow; Alvaro Alonso Journal: Obesity (Silver Spring) Date: 2011-04-07 Impact factor: 5.002